NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and TWYNEO, today announced that the Company will virtually present at the H.C. Wainwright 25^th Annual Global Investment Conference, being held September 11-13, 2023.

Presentation Information

About Sol-Gel Technologies

Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products for the treatment of skin diseases. Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of inflammatory lesions of rosacea in adults. Both drugs are exclusively licensed to and commercialized by Galderma in the U.S.

The Company’s pipeline includes Orphan Drug candidate, SGT-610 under investigation for the prevention of new basal cell carcinomas in Gorlin syndrome patients, and also includes topical drug candidate SGT-210 for the treatment of rare skin keratodermas, which had positive results in a Phase 1 study.

For additional information, please visit www.sol-gel.com.

For further information, please contact:

Investors:

Irina Koffler
Investor relations, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1 917 734 7387

Sol-Gel Technologies

Gilad Mamlok
Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.